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The reaction mechanisms of C3 are central  to both the classical and alternative 
pathways of complement activation and have in consequence been extensively studied 
(see  1 and 2 for reviews). The activation of C3 by cleavage to C3b is brought about 
by the C3-converting enzymes of the classical and alternative pathways, as well as by 
a number ofnoncomplement enzymes. C3b is subsequently inactivated and prevented 
from further participation in the C3b feedback cycle and in the hemolytic reaction by 
cleavage to C3bi by factor I, which splits C3b when the latter is combined with factor 
H. C3bi is the C3 conversion product that appears in serum in vitro after complement 
activation by either pathway, and it is fairly clear that  the C3  product, which was 
known as "beta  1A" in much of the earlier complement literature, is C3bi and not 
C3c,  the fragment with  which  beta  1A has usually been identified  (3).  C3bi  does, 
however, undergo further breakdown  both in serum  and  when  cell bound.  It was 
originally shown by Lachmann and Mi.iller-Eberhard (4) that the conglutinable form 
of C3 bound on cells (cell-bound C3bi) could be cleaved by 1/~g/ml of trypsin to lose 
its conglutinability. This was accompanied by the elution of C3c from the cell, C3d 
remaining bound.  In serum,  too, C3  gave rise, on aging,  to two fragments, one of 
which was described as beta 1A and the other, a fast-migrating fragment, as alpha 2D 
(5).  Alpha  2D was  generally equated with  C3d  (3).  As will be pointed out  in  this 
paper, this identification is not wholly correct. 
Antigenic  analysis  with  polyclonal  antisera  to  C3  had  shown  the  existence  of 
distinct antigenic specificities in C3a, C3c, and C3d, as well as antigenic determinants 
found only in native C3 (5, 6). Studies with monoclonal anti-C3 antibodies (7) showed 
one that reacted with C3c, one with C3d, and one that showed an unusual pattern of 
reactivity that has now been found to react with the fragment here called C3g. By the 
use of the monoclonal antibodies, the breakdown of C3bi both on cells and in plasma 
has been reinvestigated, and the results of this investigation are presented herein. 
Materials and Methods 
Monoclonal Anti-C3  Antibodies.  The  three  monoclonal  antibodies  are  described  as  clone  3, 
clone 4, and clone 9 and have been fully described  (7). Unless stated to the contrary, ascites 
from tumor-bearing rats was  used  as  the source  of monoclonal antibodies without  further 
purification. 
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Where the monoclonal antibodies were labeled with 12sI, immunoglobulin  G (IgG) fractions 
of the ascites  were  prepared by fractionation on DEAE-Cellulose. Iodination of monoclonal 
antibodies was performed using the iodogen procedure (8), and offering 1 mCi of 125I for every 
mg of protein. 
Complement Components.  C3 was purified at the Scripps Clinic and Research Foundation by 
the method of Tack and Prahl (9), and at the Medical Research Council Centre by the method 
of Harrison and Lachmann (10). C3 was radiolabeled both by the iodogen procedure and by 
the Bolton and Hunter (11) procedure. Factor H was purified as described in (10). Factor I was 
purified substantially as described in (4). Bovine conglutinin was purified from bovine serum 
as described (12). Cobra venom factor was purified from Naja Naja venom as described (13). 
Enzymes.  The enzymes thermolysin, cathepsin G, leukocyte elastase,  and kallikrein were 
kindly donated by Dr.  Alan Barrett  of the  Strangeways Laboratory, Cambridge, England. 
Trypsin was  purchased  from  Sigma  Chemical  Co.,  Ltd.,  London,  England.  Plasmin was 
purified by chromatography of whole plasma on Sepharose-lysine, which is used as an early 
step in the fractionation of C3  (10). Sepharose-lysine columns, after extensive washing, were 
eluted with 0.2 M epsilon-aminocaproic  acid, and the plasminogen dialyzed and concentrated 
by uhrafihration. Plasminogen  was activated with streptokinase obtained from Sigma Chemical 
Co., Ltd. The amount of streptokinase used was titrated to obtain optimal lysis of fibrin on a 
fibrin plate. The concentration of plasminogen was compared with that in undiluted human 
serum, again assessed by lysis of a  fibrin plate. The fibrin plates were prepared as described 
(14), and plasminogen concentrations  were measured by the diameter of the zone of fibrinolysis 
produced. 
Complement Intermediates.  The preparation of sheep erythrocytes (E), 1 their sensitization with 
antibody (preparation of EA), and the preparation of yeast-treated human and guinea pig 
complement (R3 reagents) were performed as described (15). The intermediate EA treated with 
complement (EAC) was made by treating 1 ml of 10% EA with 1 ml of human R3 reagent for 
2 min at  37°C followed  by washing. This intermediate contains, as far as C3 fragments are 
concerned, a mixture of C3b and C3bi. More defined intermediates were made as follows:  I ml 
of 10% EA was treated with  1 ml of guinea pig R3 reagent for 5 min at 37°C to make the 
intermediate EAC 142. The mixture, after incubation, was chilled to 4°C and washed rapidly. 
It was then treated with C3  using  1 mg of C3  for  1 ml of  10%  EACt42.  Incubation was 
continued for  15 min at  37°C with stirring. The EAC3b was washed and used as such. To 
convert EAC3b to EAC3bi, the cells were treated with purified preparations of factor H  and 
factor I for  15 min at 37°C. The EAC3bi were washed and used as such. To convert EAC3bi 
to EAC3d, the cells were treated with a final concentration of 2 #g/ml of trypsin for 5 min at 
37°C. The cells were then spun down and resuspended in a concentration of 5/zg/ml of soy 
bean trypsin inhibitor and washed twice more. The treatment of EAC3bi with enzymes other 
than trypsin is described in Results. 
Polyvalent Antisera.  Polyvalent antibody to C3 reacting with both C3c and C3d was kindly 
given by Dr. J. Bradwell, Immunodiagnostic  Research Laboratories, University  of Birmingham, 
Birmingham, England. An antiserum reacting predominantly with C3d was kindly given by 
Ortho Diagnostics, Raritan, NJ. An antiserum reacting exclusively with C3c was given by Dr. 
H.  Mi]ller-Eberhard, Scripps Clinic and Research Foundation. Anti-rat IgG antiserum was 
raised by immunization of a rabbit with rat IgG. This antiserum was absorbed with EAC for 
use in the agglutination and agglutination inhibition  reactions. 
Coprecipitation Assays.  In these assays, immunoelectrophoresis was performed on microscope 
slides.  1% agarose in 0.05 M  veronal buffer, pH 8.6, was used as support, and electrophoresis 
was carried out at 7 mA/slide at 4°C until the albumin Bromophenol blue marker had reached 
the end of the slide. The antibody slots were filled with a mixture of polyclonal anti-C3 and 
~25I-labeled monoclonal antibodies. Development was allowed to take place for 24-48 h. The 
slides were then exhaustively washed, dried, stained with Coomassie Brilliant Blue, and dried 
again. Finally, they were submitted to autoradiography, usually allowing an exposure of 1-3 d. 
Agglutination  Assay for Monoclonal Antibodies.  Monoclonal antibodies were titrated in three 
steps in microtiter plates using 50-/zl vol. 50/tl of 0.5% of complement intermediate cells were 
a Abbreviations used in this paper." E, sheep erythrocytes; EA, erythrocyte antibody; EAC, EA treated with 
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added and mixed well. The cells were allowed to settle completely at 4°C and then read for 
agglutination. At  this stage,  agglutination titers were very low and were not recorded.  The 
plates were then centrifuged for 1 rain at 1,000 rpm, and the supernatant was gently shaken off. 
The cells  were  resuspended in 50 #1  of rabbit anti-rat IgG, diluted  1:400.  Cells were  then 
allowed to settle once more, and the agglutination patterns read visually. 
Assay of C3 Fragments by Inhibition of Agglutination.  Sources  of C3 fragments were diluted in 
microtiter trays in 50-~1 vol, and 50 #1 of the monoclonal antibody was added (ascites diluted 
1:250,000) and the mixture incubated for 1 h at 4°C. The plates were then centrifuged at 1,000 
rpm for  1 min and the supernate gently shaken off. The cells were resuspended in 50/~1 1:400 
sheep anti-rat IgG and allowed to settle.  Agglutination  was read by pattern. 
Polyacrylamide Gel Electrophoresis (PAGE).  PAGE  analysis was  carried  out  by  standard 
techniques (16). 
Results 
The Antigenic Determinants Recognized by Three Monoclonal Antibodies Against C3 
REACTION WITH CELL-BOUND C3  STUDIED BY  ANTIGLOBULIN AGGLUTINATION REAC- 
TIONS.  Table I shows the agglutination titers obtained. Clone 3 and clone 4 show the 
reactivity to be expected of anti-C3d and anti-C3c, respectively. Weak reactivity of 
clone 4  is, however, seen with EAC3d cells. This can be ascribed to the  fixation of 
some C3 to EACI42 in a  form that is insusceptible to cleavage by I  and H. Clone 9 
reacts  exclusively with  a  neoantigen exposed in C3bi. To  this  extent  it  resembles 
bovine conglutinin, which reacts with a  carbohydrate determinant exposed only in 
C3bi (4). Clone 9 however, does not react with the same determinant as conglutinin. 
Thus, the reaction of clone 9, unlike that of conglutinin, is not dependent on calcium 
or inhibited by EDTA. Clone 9 is not inhibited by 0. I M  N-acetylglucosamine,  which 
inhibits  conglutination  (17),  nor  does  it  react  with  zymosan  in  the  absence  of 
complement as conglutinin does (18)  (data not shown). 
STUDIES BY COPRECIPITATION  USING RADIOLABELED MONOCLONAL ANTIBODIES  AND THE 
BREAKDOWN PRODUCTS OF PURIFIED C3 AND OF C3 IN SERUM.  In these experiments the 
source of C3 is subjected to electrophoresis and then precipitated with a  polyvalent 
anti-C3  antibody,  to  which  is  added  a  radiolabeled  monoclonal antibody.  Two 
precautions have been found necessary. One is to use only one monoclonal antibody 
on each  slide.  Because monoclonal antibodies have been found to  diffuse through 
TABLE  I 
Reaction of Monoclonal Anti-C3 Antibodies with Complement Intermediates by 
Antiglobulin Agglutination 
Cell intermediate 
EAC  EAC3b  EAC3bi  EAC3d 
Clone 3  729  2187  2187  2187 
Clone 4  243  729  2187  81 (3) 
Clone 9  243  0  243  0 
Bovine K  +++  0  +++  0 
Cell intermediates were made as described in Materials and Methods. Cells 
were incubated with  dilutions of the  monoclonal antibodies, washed, and 
finally agglutinated by anti-rat  Ig. Figures shown are the highest dilutions 
giving agglutination. Figure in parentheses is a prozone. Reactions with bovine 
conglutinin (bovine K) (10 minimal agglutinating doses) were performed by 
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precipitin lines (7), they can produce staining of lines in unexpected parts of the slide, 
which  can  cause  confusion  if more  than  one  monoclonal  antibody  is present  on  a 
slide. A  further problem is that  changes in  the antigenic structure of C3  may occur 
after electrophoresis, so that  a  line in the C3 position might be C3b or even C3bi or 
a  line in the C3b/C3bi position might be a  mixture of C3c and C3d. To minimize the 
risk of post-electrophoretic breakdown, only purified IgG fractions have been used as 
antisera  in  the  trough.  It  can  be  seen  (Fig.  1)  that  C3b  and  C3bi  cannot  be 
distinguished by their electrophoretic mobility in these conditions and both give lines 
in the "beta  1A" position. 
C3bi is split to C3c and C3d by trypsin. C3c is slightly faster in mobility than C3bi 
and C3d  is slightly slower. This is in contrast to  the situation using the aged, cobra 
venom-treated serum, which contains C3c and a  faster fragment precipitated by anti- 
C3d.  This  fragment  is alpha  2D  and  is the  C3d-containing  fragment  generated  by 
enzymes occurring in human serum. 
On  autoradiography  clone  3  (anti-C3d)  reacts  as  expected  with  C3,  C3b,  C3bi, 
C3d, and the C3 in normal human serum but not with C3c. Clone 4  (anti-C3c) reacts 
with C3, C3b, C3bi, and C3c, but not with C3d or alpha 2D.  Clone 9  reacts with C3 
and with C3b  (which was unexpected, as it failed to react  with cell-bound C3b).  It 
reacts strongly with C3bi but with neither of the two trypsin digest products shown 
by precipitation--C3c and  C3d.  On  the other hand,  it does react  strongly with  the 
alpha 2D  line. There  are, therefore,  at  least two differences between  alpha 2D  and 
FIG.  i.  Coprecipitation  assay using radiolabeled monoclonal antibodies.  Immunoelectrophoreses 
were set up as shown in top row and electrophoresed until the albumin marker reached the right 
hand end of the slide. After development, washing, and staining for protein  (2nd row) autoradiog- 
raphy was performed. C3 was used at 1 mg/ml, and the breakdown products were generated from 
this with little dilution, as follows: C3b was generated from C3 using EAC142 (0.1 ml packed cells/ 
mg C3 for 30 min at 37°C); C3bi was generated from C3b using purified factors I and H (1% by 
weight of C3b treated)  for 1 h at 37°C; C3c +  C3d was generated  from C3bi by cleavage with 
trypsin 2/~g/ml for 10 min at 37°C. The reagents made from whole serum (NHS) containing 0.01 
M azide were: NHS/CVF, serum treated with 5/~g purified CVF/ml for 45 min at 37°C; NHS/ 
CVF/aged, NHS/CVF incubated at 37°C for 20 h; NHS/CVF/aged (60°C 1 h), NHS/CVF/aged 
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C3d.  They  differ  in  electrophoretic  mobility,  and  alpha  2D  carries  the  antigenic 
determinant reacting with clone 9, whereas C3d does not. 
Does  T~ypsin Digestion  of C3bi  Produce a Nonprecipitable  Fragment Reacting  with  Clone 
9?  To answer this question, C3 fragments were tested for their ability to inhibit the 
binding of clone 9 to EAC3bi. Table II shows the results for the C3 fragments tested 
by the inhibition assay described in Materials and Methods. Purified C3 gives much 
better  inhibition  of clone  3  and  clone  4  than  it  does  of clone  9.  A  variety of C3 
preparations  have  been  tested,  and  the  more  native  preparations  give  the  lower 
inhibition  of clone 9. C3b does not inhibit clone 9 at the concentrations tested, and 
one may therefore conclude  that  the clone 9-reactive antigen  is  not  exposed.  C3bi 
inhibits all three monoclonal antibodies well. Of particular interest is the result with 
the  tryptic digest  of C3bi,  which  on precipitation  analysis shows only C3c  +  C3d. 
This digest inhibits clone 9 well and therefore must contain a  fragment carrying the 
determinant for clone 9 that is not capable of being precipitated. It is proposed to call 
this fragment C3g. 
The Size of Alpha 2D and C3d.  Alpha 2D, by virtue of containing C3g, should  be 
larger than C3d. To see whether this was the case, immunoelectrophoresis was carried 
out on serum that had been supplemented with ~25I-C3 and then treated with cobra 
venom factor (CVF)  at  37°C  for 20 h;  using anti-C3d  antiserum  to precipitate the 
alpha  2D  formed.  The  anodal  part  of the  alpha  2D  line,  which  can  readily  be 
separated  from  the  C3c  line,  was  cut  from  the  immunoelectrophoretic  plate  the 
agarose gel broken up by freezing and thawing, and the protein was eluted by boiling 
with sodium dodecyl sulfate. This alpha 2D preparation was then subjected to PAGE 
and autoradiography and compared with C3 and a tryptic digest of C3bi. The results 
are shown in Fig. 2. It can be seen that the alpha 2D is ~8K larger at 41K than is the 
C3d  fragment  at  33K.  A  low  molecular  weight  band  can  be  seen  on  the  track 
containing trypsin-digested C3bi but cannot be given a size on this gel. 
Can Cell-bound?C3bi be Converted to Cell-bound Alpha 2D?  The summary of the reaction 
of the three monoclonal antibodies with soluble C3 fragments is shown in the upper 
part  of Table  III.  It  can  be  seen  that  C3bi,  alpha  2D,  C3c,  and  C3d  can  be 
distinguished by the pattern of reaction with the monoclonal antibodies. Similarly, it 
is therefore possible to detect cell-bound alpha 2D showing reaction with clone 3 and 
clone 9 but not with clone 4. Such reactivity was found initially on cells of patients 
with cold hemagglutinin disease in vivo, but in the present experiments this question 
TAm~E II 
Assay of C3 Fragments by Inhibition of Agglutination 
Fragments tested 
(undiluted = 250 ~g/ml) 
Titer of inhibition of agglutination of 
EAC3bi using: 
Clone 3  Clone 4  Clone 9 
C3  27  27  5 
C3b  81  81  0 
C3hi  81  243  243 
Trypsin-treated C3bi  81  243  243 
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Fxc.  2.  Autoradiograph  of PAGE  on  9%  polyacrylamide of alpha  2D  globulin  cut  from  an 
immunoelectrophoresis plate (track  1)  compared with a tryptic digest  of C3bi  (track  2) and with 
native C3 (track 3). Numbers on the right of the figures are molecular weights in kiloDaltons. 
TABLE III 
Summary of Specificity of Anti-C3 Monoclonal Antibodies and Bovine Conglutinin 
Reaction with soluble  Clone 4  Clone 3  Clone 9  Bovine con- 
C3 fragments  anti-c  anti-d  anti-g  glutinin 
C3  ++*  ++:~  ++  ++  +  0  0 
C3b  ++  ++  ++  ++  +  0  0 
C3bi  ++  ++  ++  ++  ++  ++  0 
C3c  ++  ++  0  0  0  0  0 
Alpha 2D  0  0  +  ++  ++  ++  0 
C3d  0  0  0  0  N/A§  ++  0 
Reaction  with  cell- 
bound C3 fragments[[ 
C3b  ++  ++  0  0 
C3bi  ++  ++  ++  ++ 
Alpha 2D  0  ++  ++  0 
C3d  0  ++  0  0 
* Coprecipitation assay: left of each pair. 
~: Inhibition of agglutination: right of each pair. 
§ Not applicable because fragment does not precipitate. 
II Binding assay or agglutination. 
was investigated by the proteolysis of cells bearing C3bi using a  variety of different 
proteolytic enzymes,  z 
For these experiments EAC3bi were treated with dilutions of various enzymes for 
30 min at 37°C, washed, and tested with monoclonal anti-C3 and bovine conglutinin. 
A  number of enzymes were tested, and the results are summarized in Table IV. Some 
2 Lachmann, P. J., C. Voak, R. G. Oldroyd, M. D. Downie, and P. C. Bevan. Analysis of C3 fragments 
found  on  red  blood  cells  coated with  complement in  vivo  and  in  vitro.  Manuscript  submitted  for 
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TABLE IV 
Proteolysis of Cell-bound C3 
211 
Concentration of enzyme (ng/ml) to destroy reactivity 
with: 
Bovine con-  Clone 3  Clone 4  Clone 9  glutinin 
Trypsin  >3000  ]  120  370 [  120 
Thermolysin  >3000  I  120  1100 [  120 
Cathepsin G  >3000  370  370  370 
Leukocyte elastase  >3000  370  370  370 
Kallikrein  >3000  >3000  >3000  >3000 
Plasmin*  >1:1  [ 1:4  >1:1 I  1:8 
Enzymes that can generate alpha 2D globulin have differential  destructive  activity 
on clone 4 and clone 9. These are boxed. At concentrations between those given in 
the two sides of the box, alpha 2D globulin is generated from C3bi. 
* Concentrations compared  with  those  generated  in  normal  human serum  with 
streptokinase. 
TABLE  V 
Loss of Conglutinin Reactivity of EAC3bi on Incubation in Serum with and without Plasmin 
EAC43bi incubated in:  Streptoki-  Lysis on fibrin 
nase  plate 
Doses ofconglutinin giving con- 
glutination after incubation at 
37°C for: 
18 h  41 h 
NHS/56°C *  -  0  8  T 
+  ++  8  / 
NHS/56°C  filtered  through  -  0  8 
Sepharose  +  ++  8  No conglutination. 
NHS/56°C  filtered  through  -  0  8  [ 
Sepharose-lysine  +  0  8 
EAC43bi at zero times need one dose of conglutinin to give positive conglutination. 
* Normal human serum heated at 56°C for 30 min. 
enzymes (thermolysin is the best example and trypsin is another)  split C3bi to alpha 
2D  at  a  lower  concentration  than  that  needed  to  bring about  the  further  split  of 
alpha 2D to C3d.  On  the other hand, leukocyte elastase and cathepsin G  cannot be 
used to make an alpha 2D intermediate, and kallikrein will not destroy C3bi at the 
concentrations tested. Plasmin in the physiological concentration range gave rise only 
to alpha 2D. 
These experiments show that the split from C3bi leading to alpha 2D is not a  split 
at an alternative site to that producing C3d, but that the two splits are sequential; a 
fragment carrying the clone 9  determinant is released when alpha 2D is converted to 
C3d. On the basis of all the findings recorded above it seems appropriate to designate 
the material hitherto called alpha 2D as C3d,g. 
What is the Physiological  Enzyme that Brings About the Split of C3bi to C3c and Alpha 21) 
(C3d,  g) in the Serum?  The reaction breaking down C3bi in the serum is slow. Even in 
cobra venom-treated serum, where all the C3  is in the form of C3bi, it requires -18 
h  to get  complete conversion of C3bi to C3c and alpha 2D.  The relevant enzyme is 212 
Clone 4 
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Fro.  3.  Schematic representation of breakdown of C3bi by noncomplement proteases. 
therefore probably present at low concentration.  From its specificity plasmin would 
seem the most likely candidate.  However, attempts to show that  the breakdown of 
C3bi  (as shown by loss of reactivity with conglutinin)  can be retarded by depleting 
plasminogen or accelerated by activation with  streptokinase have both so far been 
unsuccessful  (Table V), and this raises doubts of whether plasmin is indee  enzyme 
concerned.  However, where plasmin inhibitors  are absent  plasmin will cleave C3bi 
efficiently. 
C3g Can Be Eluted  from Complement-coated Cells.  These experiments were done using 
125I-C3. The results shown  in  Fig.  3  were done with  iodogen-labeled C3,  but  those 
obtained  by Bolton  and  Hunter  (11)  reagent  were  not  appreciably different.  The 
sequence of conversions are outlined in Fig.  3.  EAC3b was generated from EAC142 
and radiolabeled human C3. About 7% of the offered C3 was bound to the cells. The 
EAC3b was treated with I and H  to convert it to C3bi. This process was accompanied 
by the elution from the cell of 30-40% of the C3 counts (4). This material presumably 
derives from C3b that was not covalently bound to the cell surface and is eluted in 
the form of C3bi.  It has been assumed that  the specific activities of C3b  and C3bi 
remain the same. On this basis, 32,000 molecules of C3bi/erythrocyte remain in this 
particular experiment. The cells were then eluted with plasmin to release the C3c and 
to leave the alpha 2D  (C3d,g) on the cells. The specific activity of C3c (818 cps//xg) 
is higher than that of C3bi (658 cps//~g), whereas that of C3d,g is lower (253 eps//~g). 
C3d,g cells were then treated with trypsin to release the C3g. This fragment also is of 
relatively low specific activity (156  cps//xg)  compared with the starting C3, and as 
there is also very little of it, it is not surprising that radioactive C3g bands have not 
been detected.  The C3g preparation  was tested  by inhibition  of agglutination  and 
gave a titer of 27 (corresponding to ~25 #g/ml C3bi) on inhibition of clone 9 but no 
inhibition at all with clones 3 and 4. 
Discussion 
Fig. 3 shows in schematic form what we now believe to be the breakdown pattern 
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for the transposition in the alpha chain of the alpha d,g and the alpha c fragments 
(and for redesignation of the fragment there called C3e as C3g). It also shows some 
resemblance  to  that  of Nagasawa  and  Stroud  (20).  The  sequential  nature  of the 
reactions breaking down C3bi  has  now been established  both on cells and  in  free 
solution. It is clear that the initial cleavage of C3bi in serum splits the molecule into 
C3c, which in the case of cell-bound C3bi is eluted from the cell, and the intermediate 
identified as alpha 2D (C3d,g) on immunoelectrophoretic analysis. This first split of 
C3bi into C3c and C3d,g without the second split of C3d,g to C3d and C3g can be 
brought  about by low concentrations of a  number of proteolytic enzymes, notably 
trypsin,  thermolysin,  and  plasmin.  Some  other  enzymes--leucocyte elastase  and 
cathepsin G--do not produce the first split without the second. It is not possible from 
this distribution of enzymic activity to make any predictions as to the chemical nature 
of the bond split. It is presumably in the tertiary structure of the fragment that the 
fine specificity rests, which determines which of these cleavages happens  first. The 
enzymes that  bring about C3bi breakdown in vivo are still not clearly known. The 
enzyme that brings about this split extravascularly may well be plasmin, in as much 
as it has the right specificity, but we were unable to demonstrate any acceleration of 
the split with streptokinase, nor was it absent in sera passed through sepharose-lysine 
to remove plasminogen.  Thus  it  seems  that  there may be other enzymes that  are 
capable of this split. It has recently been suggested (21)  that factor I itself may split 
C3c  from cell-bound C3bi.  In  the  fluid  phase,  however,  it  has  been  shown  using 
purified components (19, 22)  that  factor I  does not split C3bi.  2 It is also not clear 
what enzymes subsequently split C3d,g to C3d and C3g. In spite of the conventional 
view to the contrary it must be doubted whether this reaction normally goes on in 
plasma  either  in  vitro  or  in  vivo.  In  vivo  data  show  that  the  final  fragment  of 
complement activation found on erythrocytes in  cold haemolytic antibody disease 
and in mesangiocapillary glomerulonephritis (23)--two of the diseases in which the 
most  intense complement activation occurs--is alpha  2D  (C3d,g)  and  not  C3d or 
C3g.  2 We have never seen C3d in aged serum, except in one instance when no sodium 
azide was  added  to  the  serum.  The split  of C3d,g  to  C3d  and  C3g  may require 
enzymes not present in normal plasma but derived from either bacteria or from the 
breakdown of cells at inflammatory sites. 
The fragment called C3g in this paper is defined by its reactivity with clone 9. It 
has been shown that this fragment is part of alpha 2D and can be cleaved from it by 
trypsin. The C3g antigenic determinant is poorly if at all present in native C3 and is 
absent  from C3b  both on  ceils  or in  solution.  The observation  that  the  anti-C3g 
antibody reacts on coprecipitation assays with C3 and C3b must be taken to represent 
changes  either  induced  subsequent  to  electrophoresis,  possibly  by  contaminating 
enzymes in the antibody, or brought about by the reaction with the polyclonal anti- 
C3  itself. This latter mechanism would be analogous  to the situation  described by 
Coombs et al.  (24)  for C4, who showed that, whereas C4 on its own does not react 
with the C4 receptor on guinea pig erythrocytes, complexes of C4 and anti-C4 will 
indeed do so. C3g is, however, well exposed in both C3bi and in alpha 2D, which we 
now  propose should  be called  C3d,g.  To this  extent  C3g  antigen  is  a  neoantigen 
appearing on complement activation, and anti-C3g may therefore find a  use in the 
demonstration of complement activation products. C3e, as a separate acidic fragment 
of complement, was described by Ghebrihewet and MiJller-Eberhard (25), and they 214  BREAKDOWN OF C3  AFTER COMPLEMENT ACTIVATION 
identified their fragment with the leukocytosis-inducing fragment earlier described by 
Rother  (26).  C3g  as  defined  by  reactivity  with  clone  9  resembles  the  fragment 
described by Ghebrihewet and Miiller-Eberhard  (25)  approximately with respect to 
molecular weight and to a highly anodal mobility (because alpha 2D is so much more 
anodal than C3d). However, C3e was derived from C3c, whereas the present fragment 
is undoubtedly  derived  from alpha 2D and is not present  in  C3c.  Furthermore,  we 
have been unable to precipitate C3g with any of the polyclonal anti-C3 sera available 
to us, including that used to precipitate C3e in the earlier study of Ghebrihewet and 
Mfiller-Eberhard (25).  We were unable to produce precipitation even with a mixture 
of clone 9 and polyvalent antisera, suggesting that it is difficult to make antibodies to 
more than one (or two) C3g determinants. 
The  biological  properties  of the  C3g  will  be  reported  together  with  details  of 
purification in a separate publication, but preliminary testing failed to show consistent 
production  of leucocytosis  in  rabbits.  The  identification  of C3g  with  the  C3e  of 
Ghebrihewet and Miiller-Eberhard is therefore unlikely and it is probably a hitherto 
unrecognized C3 fragment. 
Summary 
The  physiological breakdown  of C3  has been studied  using  monoclonal  anti-C3 
antibodies, and it has been found that the later stages of this process--the breakdown 
of C3bi--is more complex than had previously been recognized. C3bi is the reaction 
product produced from C3b by the action of factor I which, in the presence of factor 
H, produces a double cleavage in the alpha chain of C3b. 
It is here reported that, both on cells and in the fluid phase, the breakdown of C3bi 
in  serum  gives rise  to  two  products:  C3c  and  the  product  previously  described  as 
alpha 2D, which we now propose to designate C3d,g. Alpha 2D differs from C3d in 
that it contains an additional  fragment of ~8,000 mol wt that carries the antigenic 
determinant for the clone 9 monoclonal anti-C3 antibody. C3g cannot be precipitated 
by anti-C3 antisera and therefore behaves as a  uni- or bideterminant  antigen.  The 
cleavage of C3d,g  to  C3d  and  C3g does  not  occur in  sterile  serum.  It  is also still 
uncertain what enzyme cleaves C3bi to C3c and C3d,g in plasma. Plasmin can do so 
in vitro, but plasminogen-depleted serum can still produce the cleavage. The antigenic 
determinant recognized by clone 9 in C3 is not exposed in C3 or C3b, but appears as 
a neoantigen in C3bi (and in C3d,g). Anti-C3g therefore is a potentially useful ligand 
for detecting complement-activation products.  C3g represents a  new, highly anionic 
C3 fragment and seems not to be identical with the C3e fragment described by others. 
We thank Dr. Alan Barrett for generously supplying proteolytic enzymes; Dr. Joe Bradwell and 
Ortho Diagnostics  for supplying anti-C3 antisera; Lisa B. McGuire and Robin Lachmann for 
technical assistance;  and Jane Pearson and Sarah Coppendale for help with the manuscript. 
Dr. Hans Miiller-Eberhard is particularly thanked for his hospitality to Dr~ Lachmann during 
his stay at the Scripps Clinic and Research Foundation. 
Received  for publication 22 December 1981 and in revised  form 22 March  1982. 
References 
1.  Lachmann, P. J.  1079. Complement. In The Antigens.  M.  Sela,  editor. Academic Press, 
Inc., New York. 5:983. P. J.  LACHMANN, M.  K.  PANGBURN,  AND  R.  G.  OLDROYD  215 
2.  Miiller-Eberhard, H. J., and R. D. Schreiber. 1980.  Molecular biology and chemistry of 
the alternative pathway of complement. Adv. Immunol. 29:1. 
3.  Bokisch, V. A., H. J. Miiller-Eberhard, and C. G. Cochrane.  1969. Isolation of a fragment 
(C3a)  of the  third  component  of human  complement  containing  anaphylatoxin  and 
chemotactic activity and description of anaphylatoxin inactivator of human serum. J. Exp. 
Med. 129:1109. 
4.  Lachmann, P. J., and H. J. Miiller-Eberhard. 1968. The demonstration in human serum 
of "conglutinogen activating factor" and its effect on the third component of complement. 
J. Immunol. 100:691. 
5.  West,  C.  D.,  N.  C.  Davis, J.  Forristal, J.  Herbst,  and  R.  Spitzer.  1966. Antigenic 
determinants of human beta 1C and beta 1G globulins.J, lmmunol. 96:650. 
6.  Molenaar, J. L., A. T. Velde, and K. W. Pondman.  1973. Anti-C3a, anti-C3b (anti-B) and 
their reaction with the anaphylactic fragment C3a. J. Immunol. 110: 702. 
7.  Lachmann,  P.  J.,  R.  G.  Oldroyd,  C.  Millstein,  and  B.  W.  Wright.  1980. Three  rat 
monoclonal antibodies to human C3. Immunology. t1:503. 
8.  Fraker, P. J., andJ. C. Speck. 1978. Protein and cell membrane iodinations with a sparingly 
soluble chloroamide,  1,3,4,6-tetrachloro-3a,  6a-diphenylglycoluril. Biochem. Biophys. Res. 
Commun. 80:849. 
9.  Tack, B. F., and J. W. Prahl. 1976. Third component of human complement: purification 
from plasma and physicochemical characterization. Biochemistry. 15:4513. 
10.  Harrison, R. A., and P. J. Lachmann.  1979. An improved purification procedure for the 
third component of complement and beta 1H globulin from human serum. Mol. Immunol. 
16: 767. 
11.  Bolton,  A.  E.,  and  W.  M.  Hunter.  1973. The  labeling  of proteins  to  high  specific 
radioactivities by conjugation to a a25I-containing acylating agent. Biochem.  J.  133:529. 
12.  Lachmann, P.J.  1967. Conglutinin and immunoconglutinins. Adv. Immunol. 6:480. 
13.  Ballow, M., and C. G. Cochrane.  1969. Two anti-complementary factors in cobra venom. 
Haemolysis of guinea-pig erythrocytes by one of them.J. Immunol. 103:944. 
14.  Hobart, M.J. 1979. Genetic polymorphism of human plasminogen. Ann. Hum. Genet. 42:419. 
15.  Lachmann,  P. J.,  and  M. J.  Hobart.  1978.  Complement  Technology. In  Handbook of 
Experimental Immunology. D. M. Wier, editor. Blackwell Scientific Publications, Oxford. 
5A. 1-23 
16.  Laemmli, U. K.  1970. Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature (Lond.).  227:680. 
17.  Yokohari, R., and M.  A. Leon.  1965.  Isolation of calcium dependent bovine antibodies. 
Fed. Proc. 24:635. 
18.  Lachmann, P.J.  1962. A comparison of some properties of bovine conglutinin with those 
of rabbit immunoconglutinin. Immunology. 5:687. 
19.  Harrison, R.  A., and  P. J.  Lachmann.  1980.  The  physiological breakdown of the third 
component of human complement. Mol. Immunol. 17:9. 
20.  Nagasawa,  S.,  and  R.  M.  Stroud.  1977. Mechanism  of action of the  C3b  inactivator: 
requirement for a high molecular weight cofactor (C3b-C4b INA cofactor) and production 
of a new C3b derivative (C3b~). Immunochemist~y. 14:749. 
21.  Medicus,  R.  G.,  and  M.  D.  Arnaout.  1982. Release of C3  from  bound  C3bi  by  C3b 
inactivator. Mol. Immunol. In press. 
22.  Pangburn, M. K., R. D. Schreiber, and H. J. Miiller-Eberhard. 1977. Human complement 
C3b inactivator: isolation, characterization, and demonstration of an absolute requirement 
for the serum protein BIH for cleavage of C3b and C4b in solution.J. Exp. Med. 146:257. 
23.  West, C. D., S. Winter, J. Forristal, J. M. McConville, and N. C. Davis. 1967. Evidence for 
in vivo breakdown of beta 1C globulin in hypocomplementemic glomerulonephritis.J. Clin. 
Invest. 46:539. 216  BREAKDOWN OF C3  AFTER  COMPLEMENT  ACTIVATION 
24.  Coombs,  R.  R.  A.,  A.  B.  Wilson,  and  P.  J.  Lachmann.  1980. The  coagglutination 
phenomenon of Bordet  and  Gengou  involves a  reaction  between  antibody-aggregated 
fourth component of complement and a receptor on guinea pig red cells. Int. Arch. Allergy 
Appl.  Immunol. 61:371. 
25.  Ghebrehiwet, B., and H. J. Miiller-Eberhard. 1979. C3e: an acidic fragment of human C3 
with leucocytosis  inducing activity. J. Immunol. 123:616. 
27.  Rother,  K.  1972. Leukocyte mobilizing factor:  a  new biological activity from the third 
component of complement. Eur. J. Immunol. 2:550. 